

ASX ANNOUNCEMENT

Results of 2016 Annual General Meeting

24 November 2016

Analytica Limited (ASX: ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

Resolution Number	Resolution Name	For resolution	Open votes held by the Chair (for resolution)	Against resolution	Abstain from voting
1	Remuneration report	398,391,067 87.0%	13,591,787 3.0%	45,746,942 10.0%	4,101,533 -
2	Re-election of Mr Ross Mangelsdorf	1,006,587,659 97.0%	14,312,332 1.4%	16,460,207 1.6%	23,943,672 -
3	Ratification of March 2016 placement	975,136,675 96.9%	13,812,332 1.4%	17,757,346 1.7%	1,497,517 -
4	Ratification of April 2016 placement	754,383,466 95.9%	13,812,332 1.8%	17,757,346 2.3%	1,597,517 -
5	Ratification of September 2016 placement	754,062,706 95.9%	13,812,332 1.8%	18,078,106 2.3%	1,597,517 -
6	Ratification of October 2016 placement	752,595,597 95.8%	14,259,441 1.8%	19,098,106 2.4%	1,597,517 -
7	Special Resolution - Approval of Enhanced Placement Capacity	995,025,082 93.8%	13,812,332 1.3%	52,292,749 4.9%	173,707 -
8	Grant of options to Dr Michael Monsour	485,869,124 86.6%	18,229,580 3.3%	56,880,877 10.1%	20,000 -
9	Grant of options to Mr Warren Brooks	943,523,687 93.2%	5,365,877 0.5%	63,721,181 6.3%	48,645,000 -
10	Grant of options to Dr Thomas Lönngren	985,498,445 92.9%	12,036,119 1.1%	63,721,181 6.0%	48,125 -
11	Grant of options to Mr Ross Mangelsdorf	950,111,780 92.6%	12,036,119 1.2%	63,721,181 6.2%	48,125 -
12	Grant of options to Mr Carl Stubbings	984,818,945 92.8%	12,715,619 1.2%	63,598,959 6.0%	170,347 -

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com





Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.